Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

This study has been completed.

Sponsor:

Information provided by:

Innovative Medical

ClinicalTrials.gov Identifier:

NCT00347802

First received: June 30, 2006

Last updated: May 30, 2007

Last verified: May 2007

History of Changes

Tracking Information

First Received Date ^ICMJE

June 30, 2006

Last Updated Date

May 30, 2007

Start Date ^ICMJE

Not Provided

Primary Completion Date

Not Provided

Current Primary Outcome Measures ^ICMJE

Not Provided

Original Primary Outcome Measures ^ICMJE

Not Provided

Change History

Complete list of historical versions of study NCT00347802 on ClinicalTrials.gov Archive Site

Current Secondary Outcome Measures ^ICMJE

Not Provided

Original Secondary Outcome Measures ^ICMJE

Not Provided

Current Other Outcome Measures ^ICMJE

Not Provided

Original Other Outcome Measures ^ICMJE

Not Provided

Descriptive Information

Brief Title ^ICMJE

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Official Title ^ICMJE

Diurnal Curves With Bimatoprost 0.03% Versus Travoprost 0.004%

Brief Summary

To compare the diurnal curves in patients using bimatoprost 0.03% versus travoprost 0.004% for the treatment of glaucoma or ocular hypertension.

Detailed Description

Not Provided

Study Type ^ICMJE

Interventional

Study Phase

Phase 4

Study Design ^ICMJE

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind

Condition ^ICMJE

Glaucoma

Intervention ^ICMJE

Drug: Bimatoprost 0.03%, Travoprost 0.004%

Study Arm (s)

Not Provided

Publications *

Not Provided

* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information

Recruitment Status ^ICMJE

Completed

Enrollment ^ICMJE

Not Provided

Completion Date

Not Provided

Primary Completion Date

Not Provided

Eligibility Criteria ^ICMJE

Inclusion Criteria:

· Male or female > 18 years of age
- Naive to treatment or washed off any ocular hypotensive agents
- Untreated IOP >19 mm Hg
- Diagnosis of open-angle glaucoma or ocular hypertension
- Ability to provide informed consent and likely to complete study

Exclusion Criteria:

· Known contraindication to bimatoprost or travoprost, or any component of any study medication
- Uncontrolled systemic disease
- Active ocular disease other than glaucoma or ocular hypertension
- Required use of ocular medications other than the study medications during the study
- History of intraocular surgery within the last 3 months
- Prior discontinuation of any of the study medications for reasons related to efficacy or safety

Gender

Both

Ages

18 Years and older

Accepts Healthy Volunteers

Not Provided

Contacts ^ICMJE

Contact information is only displayed when the study is recruiting subjects

Location Countries ^ICMJE

United States

Administrative Information

NCT Number ^ICMJE

NCT00347802

Other Study ID Numbers ^ICMJE

5176

Has Data Monitoring Committee

Not Provided

Responsible Party

Not Provided

Study Sponsor ^ICMJE

Innovative Medical

Collaborators ^ICMJE

Not Provided

Investigators ^ICMJE

Principal Investigator:

Robert Noecker, MD

UPMC Eye Center

Information Provided By

Innovative Medical

Verification Date

May 2007

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top